Vimarsana
Biggest News Aggregation in the World

Page 2 - Primary Iga News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Primary Iga. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Primary Iga Today - Breaking & Trending Today

Calliditas Therapeutics to Present Nefecon Data at the 17th International Symposium on IgA Nephropathy (IIgANN) Septembe - Vimarsana News

Calliditas Therapeutics to Present Nefecon Data at the 17th International Symposium on IgA Nephropathy (IIgANN) Septembe

Published: September 19, 2023

STOCKHOLM, Sept. 19, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm:...

Source: europapress.es
Related Topics:
Hong ZhangRichard LafayetteHeathern ReichAndrew StoneVladimir TesarNadia NawazRoisin ThomasBradh RovinJens KristensenKaren MolyneuxJonathan BarrattAlexander PaliegeUniversity Of LeicesterInternational Symposium On Iga Nephropathy IigExchange CommissionNasdaq StockholmNeflgard PhaseInternational SymposiumIga NephropathyPrimary IgaPresentation DetailsNefigard PartNefigard PhaseNecmi ErenVicky Cotton
Calliditas Therapeutics announces full results from the NefIgArd Phase 3 trial published in The Lancet (1) - Vimarsana News

Calliditas Therapeutics announces full results from the NefIgArd Phase 3 trial published in The Lancet (1)

Published: August 15, 2023

STOCKHOLM, Aug. 15, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX)...

Source: europapress.es
Related Topics:
United StatesUnited KingdomJonathanm BarrattUnited States Federal Drug AdministrationEuropean Union Member StatesUniversity Of LeicesterEuropean CommissionExchange CommissionNasdaq StockholmIgard StudyPrimary IgaMayer ProfessorRenal MedicineChief Executive OfficerInvestor RelationsFull PrescribingIga NephropathyPrimary ImmunoglobulinAmerican Depositary SharesNasdaq Global Select MarketPrivate Securities Litigation Reform Act
Calliditas Therapeutics announces full results from the NefIgArd Phase 3 trial published in The Lancet - Vimarsana News

Calliditas Therapeutics announces full results from the NefIgArd Phase 3 trial published in The Lancet

Published: August 15, 2023

/PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced publication in The Lancet of the full data...

Source: prnewswire.com
Related Topics:
United KingdomUnited StatesJonathanm BarrattEuropean CommissionExchange CommissionUnited States Federal Drug AdministrationUniversity Of LeicesterEuropean Union Member StatesNasdaq StockholmIgard StudyPrimary IgaMayer ProfessorRenal MedicineChief Executive OfficerInvestor RelationsFull PrescribingIga NephropathyPrimary ImmunoglobulinAmerican Depositary SharesNasdaq Global Select MarketPrivate Securities Litigation Reform ActCalliditas Therapeutics
Calliditas Therapeutics announces full results from the NefIgArd Phase 3 trial published in The Lancet (2) - Vimarsana News

Calliditas Therapeutics announces full results from the NefIgArd Phase 3 trial published in The Lancet (2)

Published: August 15, 2023

STOCKHOLM, Aug. 15, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX)...

Source: europapress.es
Related Topics:
United KingdomUnited StatesJonathanm BarrattUniversity Of LeicesterEuropean Union Member StatesUnited States Federal Drug AdministrationEuropean CommissionExchange CommissionNasdaq StockholmIgard StudyPrimary IgaMayer ProfessorRenal MedicineChief Executive OfficerInvestor RelationsFull PrescribingIga NephropathyPrimary ImmunoglobulinAmerican Depositary SharesNasdaq Global Select MarketPrivate Securities Litigation Reform Act